[slide 1]
Appeals Conference Presentation — Penterra Pharmaceuticals Corp. Transfer Pricing Defense
Penterra Pharmaceuticals Corp. — IRS Transfer Pricing Examination Defense
Tax Years 2017, 2018, 2019, 2020
IRS Appeals Conference — February 28, 2024
IRS Appeals Office, Manhattan
Presented by Calderwood & Harkness LLP
Matter No. 1018-00009
PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT
[slide 2]
Agenda
1. Case Overview and Procedural History
2. Penterra Corporate Structure and IP Architecture
3. IRS Proposed Adjustments — $380.4M Summary
4. PPC's Transfer Pricing Positions — CSA Cost-Sharing Ratios
5. PPC's Transfer Pricing Positions — Legacy IP Royalty Rate
6. PCT Valuation Analysis
7. PBI Economic Substance and DEMPE Functions
8. Penalty Protection and Contemporaneous Documentation
9. Hazards of Litigation — Both Sides
10. Proposed Resolution Framework
[slide 3]
Case Overview and Procedural History
Examination opened May 16, 2022 (Letter 2205-A) — TY 2017–2020
47 Information Document Requests issued June 2022 – September 2023
PPC cooperated fully; produced comprehensive documentation for all IDRs
Notice of Proposed Adjustment (NOPA) issued October 12, 2023 — all four years
30-Day Letter issued November 8, 2023
Formal Protest filed December 22, 2023
Case assigned to Appeals Officer Castañeda — January 2024
IRS Exam Team: SRA Gerald Meskill (Team Manager), RA Patricia Dunleavy (Lead), Dr. Alan Washburne (Economist), Franklin Rosario (Chief Counsel Attorney)
[slide 4]
Penterra Pharmaceuticals Corp. — Company Overview
Delaware corporation; publicly traded on Nasdaq (ticker: PPCA)
Headquarters: 2200 Independence Boulevard, Princeton Junction, NJ 08550
Specialty pharmaceuticals and biotechnology — oncology, immunology, rare-disease therapeutics
FY 2020 Revenue: $6.82 billion
~14,500 global employees
Key Products: Veritaxol (oncology, $3.12B global), Imvara (immunology, $1.87B global), Cerulon (rare disease, $620M global)
CEO: Catherine Falk
[slide 5]
Corporate Structure and IP Architecture
PPC (U.S. Parent, Delaware) → PHL (Luxembourg S.à r.l., disregarded entity for U.S. tax) → PBI (Ireland, DAC) → PMI (Ireland, contract manufacturer)
PBI incorporated March 15, 2012; Cost-Sharing Arrangement effective July 1, 2012
PBI: IP-holding company and principal for non-Americas commercialization
PBI acquired rights to exploit PPC IP outside the Americas via CSA
Platform Contribution Transaction (PCT) payment: $312M lump sum (July 1, 2012)
Separately, PBI licenses legacy (pre-2012) compounds from PPC at 4.5% royalty on non-Americas net sales
PMI: Contract manufacturer for biologics; cost + 8% markup arrangement with PBI
PHL: Intermediate holding entity; 100% owner of PBI; treated as disregarded entity
[slide 6]
Cost-Sharing Arrangement — Key Terms
Effective July 1, 2012 under Treas. Reg. § 1.482-7 (Qualified CSA)
PBI co-funds R&D costs in exchange for rights to exploit IP outside the Americas
PCT payment of $312M for buy-in to pre-existing IP (clinical-stage and approved oncology compounds)
Cost-sharing ratios based on Reasonably Anticipated Benefits (RAB):
— 2017: PBI share 38.2% of $487.3M = $186.15M
— 2018: PBI share 39.6% of $523.8M = $207.42M
— 2019: PBI share 41.1% of $561.2M = $230.65M
— 2020: PBI share 42.7% of $598.4M = $255.52M
RAB projections reflect growing non-Americas market share consistent with product lifecycle and regulatory approvals
[slide 7]
Legacy IP Royalty Arrangement — Key Terms
Separate intercompany license for pre-2012 (legacy) compounds not covered by CSA
Royalty rate: 4.5% of net sales in non-Americas territory
Legacy compound non-Americas net sales (declining lifecycle):
— 2017: $814.6M → royalty $36.66M
— 2018: $762.3M → royalty $34.30M
— 2019: $691.8M → royalty $31.13M
— 2020: $624.1M → royalty $28.08M
4.5% rate set at arm's length based on contemporaneous benchmarking at time of license execution
Legacy net sales declining year-over-year — products in late lifecycle
[slide 8]
Summary of IRS Proposed Adjustments — $380.4M
IRS Position 1 — CSA Cost-Sharing Ratios: Proposed increase of 8–12 percentage points per year
— 2017: +10.0pp → $48.73M
— Subtotal CSA: $235.01M
IRS Position 2 — Legacy IP Royalty Rate: Proposed increase from 4.5% to 11.0%
— Subtotal Royalty: $188.04M across four years
Correlative offset allowed by exam: ($42.65M)
Net Proposed Adjustment: $380.40M
IRS also asserted IRC § 6662(e) penalty (20%): ~$15.98M
IRS Position 3 — Economic Substance: Assertion that PBI lacked sufficient substance; key DEMPE functions remained in U.S.
[slide 9]
IRS Position on PCT Undervaluation — Background Context
IRS asserts $312M PCT payment undervalued pre-existing IP by ~$540M
IRS valued PCT at $852M using income method with 7.2% WACC and higher revenue projections
2012 (PCT year) was outside the examination period (TY 2017–2020)
IRS instead recharacterized ongoing CSA cost-sharing ratios and royalty rates as failing to reflect full IP value
IRS's adjustment theory: inadequate PCT → inadequate ongoing payments → upward adjustment to 2017–2020 income
PPC/Whitmore position: $312M is within the arm's-length range of $278M–$361M (9.8% WACC)
[slide 10]
PPC's Defense — CSA Cost-Sharing Ratios (IRC § 482 / Treas. Reg. § 1.482-7)
PBI's cost-sharing percentages (38.2%–42.7%) reflect arm's-length RAB shares
RAB methodology complies with Treas. Reg. § 1.482-7 requirements
Revenue projections used to calculate RAB were contemporaneous, reasonable, and documented
PBI bore genuine market risk for non-Americas territories and made independent commercial decisions
CPM/TNMM analysis: PBI's operating margins tested against 22 comparable companies — within interquartile range in all four years
IRS's proposed increases (48.2%–53.7%) not supported by reliable economic analysis
IRS's adjustment improperly inflates U.S.-source benefits without accounting for PBI's risk-bearing and decision-making
[slide 11]
PPC's Defense — Legacy IP Royalty Rate (Treas. Reg. § 1.482-4)
PPC's 4.5% royalty rate falls squarely within the arm's-length range
Whitmore CUT analysis identified 14 comparable uncontrolled pharmaceutical license agreements
Interquartile range of comparable royalty rates: 3.1% – 6.8%
Median comparable rate: 4.4% — PPC's 4.5% is virtually at the median
IRS's proposed 11.0% rate is well above the upper quartile of reliable comparables
IRS's selected CUTs suffer from significant comparability defects (product scope, territory, risk allocation)
Legacy compounds are in late product lifecycle with declining net sales — higher royalty rates would be economically irrational
[slide 12]
PCT Valuation — Income Method / DCF Analysis
Whitmore income method / DCF analysis: $312M PCT within arm's-length range of $278M–$361M
WACC of 9.8% — appropriate for early-stage pharmaceutical IP with inherent clinical and commercial risks
IRS used WACC of 7.2% — fails to account for pharmaceutical risk premiums, beta comparables, and industry cost of capital
Revenue projections: PPC's 2012-era projections were reasonable and consistent with industry norms
2.6 percentage-point WACC difference drives ~$540M valuation gap (IRS's $852M vs. PPC's $312M range)
Discount rate is the single most significant driver — IRS's rate is unsupported by pharmaceutical comparable data
[slide 13]
PBI Economic Substance — Rebutting the IRS Challenge
PBI headcount grew from 52 (2012) to 185 (2020) — genuine operational build-out
PBI maintained ~18,000 sq ft of dedicated office space at Sandyford Business Park, Dublin
42 board meetings held in Dublin during 2017–2020 (quarterly + special sessions)
PBI employed regulatory, medical-affairs, commercial-strategy, and supply-chain professionals
€47.2M cumulative regulatory expenditures (2017–2020) for non-Americas market submissions
Independent pricing decisions across 68 country markets outside the Americas
PBI bore genuine market risk — made key decisions on pricing, market entry, distribution partner selection
Independent banking with Glenmore Bank Ireland plc; independent treasury operations
Managing Director Aidan Naughton resident in Dublin; local management team with decision-making authority
[slide 14]
DEMPE Functions Matrix — PPC vs. PBI Allocation
Development: PPC leads R&D in U.S.; PBI co-funds via CSA and directs non-Americas clinical activities
Enhancement: PBI manages product lifecycle, formulation adaptations, and market-specific enhancements for 68 markets
Maintenance: PBI handles IP protection, regulatory maintenance, pharmacovigilance outside Americas
Protection: PBI manages IP enforcement, trademark protection, and regulatory exclusivity in its territory
Exploitation: PBI is the principal for non-Americas commercialization — pricing, marketing, distribution
Key takeaway: PBI performs substantial DEMPE functions; not a mere shell or conduit entity
Consistent with OECD Guidelines Chapter VI and case law on substance requirements
[slide 15]
Penalty Protection — IRC § 6662(e) Defense
PPC maintained contemporaneous transfer pricing documentation for all four tax years (2017–2020)
Documentation prepared by Crestfield & Associates LLP (Susan Lam, Transfer Pricing Partner) under IRC § 6662(e) penalty-protection standards
Documentation meets Treas. Reg. § 1.6662-6(d) requirements for reasonable cause and good faith
PPC selected and applied recognized transfer pricing methods (CUT, CPM, income method)
PPC's positions are within the arm's-length range supported by independent economic analysis
Reasonable cause established: PPC relied on qualified professionals and maintained thorough documentation
IRS proposed 20% penalty (~$15.98M) should be fully abated
[slide 16]
Legal Framework — Key Authorities Supporting PPC's Positions
IRC § 482 — Arm's-length standard for intercompany allocations
Treas. Reg. § 1.482-1(d) — Best method rule; most reliable method must be selected
Treas. Reg. § 1.482-4 — Arm's-length consideration for intangible property (royalty)
Treas. Reg. § 1.482-7 — Qualified cost-sharing arrangements and PCT valuation
IRC § 6662(e) — Substantial valuation misstatement penalty; § 6662(e)(3)(B) documentation safe harbor
Altera Corp. v. Commissioner — CSA methodology and stock-based compensation
Harborview Corporation, Inc. v. Commissioner — CUT method and comparability standards
OECD Transfer Pricing Guidelines (2017, 2022) — Chapters VI and VIII as persuasive authority
IRC § 367(d) — Outbound IP transfer rules (not applicable to CSA; anticipating IRS recharacterization)
[slide 17]
Rebuttal of IRS Economist's Analysis
Dr. Washburne's CUT selection for royalty rate contains significant comparability defects
IRS CUTs involve broader territory grants, different product types, and different risk profiles
IRS's 11.0% royalty rate is an outlier relative to the full set of reliable comparables
IRS's 7.2% WACC for PCT valuation fails to account for pharmaceutical-specific risk
IRS revenue projections used in PCT valuation are unreasonably optimistic for 2012-vintage forecasts
IRS's proposed CSA ratio increases lack independent benchmarking support
Whitmore's analysis (Dr. Vasquez, Dr. Chakrabarti) uses more rigorous screening criteria and reliable data
[slide 18]
Hazards of Litigation — Assessment for Both Parties
CSA Cost-Sharing: PPC's methodology well-supported; IRS faces significant burden to overcome contemporaneous documentation — moderate-to-strong PPC position
Royalty Rate: PPC's CUT analysis (14 comparables, IQR 3.1%–6.8%, median 4.4%) substantially more reliable than IRS's — strong PPC position
PCT Valuation: Discount rate dispute is the core issue; WACC disagreements are inherently factual and could go either way — moderate PPC position
Economic Substance: PBI's operational presence is extensively documented — strong PPC position
Penalty: Contemporaneous documentation clearly satisfies § 6662(e)(3)(B) — very strong PPC position
IRS faces risk of adverse precedent on all issues if litigated in Tax Court
Both parties benefit from a negotiated resolution
[slide 19]
Financial Context and Stakeholder Considerations
Proposed $380.4M adjustment → tax impact of ~$79.9M + penalty ~$16.0M = ~$95.9M total exposure
PPC FY 2020 pre-tax income: $1.47B; proposed adjustment represents ~26% of pre-tax income
PPC maintains FIN 48 (ASC 740-10) reserve of $62.4M for uncertain tax positions related to Irish IP structure
PPC publicly traded (Nasdaq: PPCA) — SEC disclosure obligations for material contingencies
Hargrove National Bank $1.5B revolving credit facility contains tax-indemnity and material-tax-event covenants
Institutional shareholders (e.g., Ridgeview Capital Management LP, 8.3% stake) monitor tax reserve disclosures
Resolution certainty benefits all stakeholders
[slide 20]
Proposed Resolution Framework
PPC's positions are well-supported — full adjustment of $380.4M is not warranted
PPC proposes resolution in the range of 10–15% of the net proposed adjustment
Settlement range: approximately $38M – $57M in total adjustments across TY 2017–2020
Full abatement of the IRC § 6662(e) penalty — contemporaneous documentation clearly satisfies the safe harbor
Allocation of any agreed adjustment across all four tax years proportionally
Execution of IRS Form 906 Closing Agreement to provide finality
PPC is prepared to work cooperatively with Appeals to reach a fair and efficient resolution
[slide 21]
Summary of PPC's Key Arguments
1. CSA cost-sharing ratios (38.2%–42.7%) reflect arm's-length RAB shares — supported by CPM/TNMM benchmarking against 22 comparables
2. Legacy IP royalty rate of 4.5% is at the median (4.4%) of 14 reliable CUT comparables (IQR: 3.1%–6.8%)
3. PCT payment of $312M is within the arm's-length range ($278M–$361M) using an appropriate 9.8% WACC
4. PBI has robust economic substance: 185 employees, 42 board meetings, €47.2M regulatory spend, 68 markets, independent banking
5. Contemporaneous documentation satisfies penalty protection under IRC § 6662(e)(3)(B)